Table 3.

Change from baseline to end of week 12 in haemodynamic variables in the subgroup of patients with PAH-CHD in Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (observed values)

	Placebo			Riociguat 2.5 mg–maximum			Riociguat 1.5 mg–maximum
	n	Baseline	Change from baseline	n	Baseline	Change from baseline	n	Baseline	Change from baseline
PVR (dyn·s/cm5)	11	1312±763	−66±632	13	1130±664	−250±410	7	1047±564	−126±368
mPAP (mm Hg)	11	61±23	+1±8	14	59±21	−4±7	7	67±19	−3±10
Cardiac index (L/min/m2)	11	2.2±0.6	+0.2±0.7	13	2.6±0.6	+0.4±0.6	7	3.3±1.4	+0.3±1.2
Right atrial pressure (mm Hg)	10	8.1±6.0	+2.7±6.4	14	8.4±5.3	−0.3±4.3	7	9.7±3.1	−1.7±2.8
Mean arterial pressure (mm Hg)	12	90±9	−3±8	14	82±13	−7±9	7	92±21	−9±9
Systemic vascular resistance (dyn·s/cm5)	10	1995±394	−287±587	13	1516±376	−307±326	7	1388±398	−278±472
Mixed venous oxygen saturation (%)	11	62±10	−3±7	13	69±8	+2±6	7	68±7	+1±6

Data are mean±SD.

CHD, congenital heart disease; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance.